SLC5A2 and diabetes mellitus: No significant publication bias was detected.<h4>Conclusions</h4>SGLT2 inhibitors significantly reduce the mortality and heart failure hospitalizations while improving the biomarker and cardiac function parameters, independent of diabetes status or heart failure phenotype.